The agreement is a positive but small step for European commercialization. Without disclosed financial terms or minimum commitments, the near-term revenue impact is uncertain. Monitor for any subsequent long-term agreement or revenue guidance, and watch the THERMAC Phase III trial for potential catalyst. Given the $8M market cap and historical volatility, even modest news can move the stock significantly.
Price Chart
Executive Summary
IceCure Medical announced an exclusive distribution agreement with Scovas Medical for its ProSense cryoablation systems in the Netherlands. The agreement supports commercialization in a market where the THERMAC trial has advanced to Phase III with a focus on cryoablation, citing a 94% success rate and 0% complication rate. This is a modest commercial expansion for a micro-cap company with an $8M market cap, but no financial terms were disclosed, limiting near-term revenue visibility.
Key Facts
- IceCure signed an exclusive distribution agreement with Scovas Medical for ProSense systems in the Netherlands.
- The agreement has an initial term with a view toward a longer-term agreement.
- The THERMAC trial in the Netherlands advanced to Phase III focusing on cryoablation, citing a 94% success rate and 0% complication rate.
- No financial terms, minimum purchase commitments, or revenue guidance were disclosed.
- The company has an $8M market cap and is a commercial-stage medical device firm with limited revenue scale.
Financial Impact
Undisclosed — no financial terms, upfront payments, or revenue projections were provided in the filing.
Risk Factors
- No financial terms disclosed — revenue contribution may be immaterial.
- Micro-cap with limited liquidity and high volatility; stock has shown extreme swings on prior filings.
- Dependence on successful THERMAC Phase III trial outcomes for broader adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-092807 |
| Document: 0001213900-26-092807-index-headers.html | 0001213900-26-092807 |
| Document: 0001213900-26-092807-index.html | 0001213900-26-092807 |
| Document: 0001213900-26-092807.txt | 0001213900-26-092807 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.10 | awaiting T+60 | — | $1.01 (−8.18%) |
Oct 5, 2026 21d ago | 6-K | $1.27 | awaiting T+60 | — | $1.01 (−20.47%) |
Oct 5, 2026 21d ago | 6-K | $1.54 | awaiting T+60 | — | $1.01 (+34.42%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.01 (−52.80%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.01 (−55.51%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.01 (+59.92%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.01 (−64.18%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.01 (−67.47%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.01 (+78.09%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.01 (+80.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers